Lipidover

Rosuvastatin Calcium, the active ingredient in Lipidover, is a statin (HMG‑CoA reductase inhibitor) presented as an oral tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adult patients, helping to lower LDL‑cholesterol and reduce cardiovascular risk.

GNH USA supplies Lipidover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. With a focus on regulatory compliance, GNH USA ensures product integrity throughout the supply chain.

Lipidover (rosuvastatin calcium) is indicated for disorders of lipid metabolism and for cardiovascular risk reduction. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Primary hyperlipidemia: reduces triglycerides and improves overall lipid profile. - Prevention of cardiovascular events in at‑risk patients: decreases incidence of myocardial infarction, stroke and related vascular events.

Adverse reactions to Lipidover vary in frequency and severity.

Common Side Effects: - Muscle pain: mild myalgia reported by some patients. - Headache: transient headache may occur. - Nausea: occasional gastrointestinal upset. - Abdominal discomfort: mild stomach pain or dyspepsia.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential renal injury. - Significant liver enzyme elevation: marked increase in ALT/AST. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Lipidover, clinicians should consider several precautionary measures. - Renal function: assess kidney function and adjust dose if necessary. - Hepatic disease: avoid use in active liver disease or unexplained persistent elevations of transaminases. - Pregnancy: contraindicated unless potential benefit justifies risk to the fetus. - Drug interactions: review concomitant medications, especially CYP3A4 inhibitors and other lipid‑lowering agents. - Monitoring: obtain baseline lipid profile and liver enzymes, and repeat periodically during therapy. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Lipidover may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure. - Gemfibrozil: combined use raises risk of myopathy. - High‑dose niacin: can potentiate muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption, monitor lipid response. - Warfarin: rosuvastatin can enhance anticoagulant effect, check INR more frequently.